<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The <z:mp ids='MP_0001845'>inflammation</z:mp> marker YKL-40 is elevated in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and is associated with <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> and increased cardiovascular mortality </plain></SENT>
<SENT sid="1" pm="."><plain>In the present study, YKL-40 levels were examined in patients with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> with increasing levels of <z:mp ids='MP_0002871'>albuminuria</z:mp>, known to be associated with an increased risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A total of 149 patients with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> attending Steno <z:mp ids='MP_0002055'>Diabetes</z:mp> Center were examined: 58 had normoalbuminuria (urinary albumin excretion rate &lt;30 mg/24 h), 46 had persistent <z:mp ids='MP_0002959'>microalbuminuria</z:mp> (urinary albumin excretion rate 30-300 mg/24 h), and 45 had persistent macroalbuminuria/diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (urinary albumin excretion rate &gt;300 mg/24 h) </plain></SENT>
<SENT sid="3" pm="."><plain>The control group consisted of 55 healthy individuals </plain></SENT>
<SENT sid="4" pm="."><plain>Groups were matched according to sex and duration of <z:mp ids='MP_0002055'>diabetes</z:mp> (&gt;30 years) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Median levels [interquartile range] of serum YKL-40 were significantly higher in normoalbuminuria versus control (37 [29-52] vs. 53 [32-105] ng/ml, P &lt; 0.01) and were increasing with increasing levels of <z:mp ids='MP_0002871'>albuminuria</z:mp> (<z:mp ids='MP_0002959'>microalbuminuria</z:mp> 74 [45-160] ng/ml and diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> 117 [68-215] ng/ml; P &lt; 0.001 for <z:hpo ids='HP_0000001'>all</z:hpo> comparisons) </plain></SENT>
<SENT sid="6" pm="."><plain>YKL-40 levels correlated with the urinary albumin-to-<z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio in the total group of participants (r2 = 0.25, P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Significant but weak intercorrelations of YKL-40 were found with age, diastolic blood pressure, A1C, and serum <z:chebi fb="0" ids="16737">creatinine</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>After adjustment for significant covariates, <z:mp ids='MP_0002871'>albuminuria</z:mp> was significantly associated with YKL-40 levels (P &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: YKL-40 levels are elevated in patients with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> with an independent association between increasing YKL-40 levels and increasing levels of <z:mp ids='MP_0002871'>albuminuria</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>The present study is the first to suggest a role of YKL-40 in the gradually progressing vascular complications in patients with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>